We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunosignaturing Platform Provides Pre-Symptom Diagnostics

By LabMedica International staff writers
Posted on 21 Feb 2017
Researchers have developed an immunosignature profiling technology aimed to provide people with a means of monitoring their health status and a means for early detection of disease by rapidly testing for many diseases at once from a single drop of blood. More...
In addition, the versatile technology could be used to secure a nation’s blood supply or give early warning of a disease epidemic.

An international group of scientists, inventors, and entrepreneurs are bringing this invention to fruition and “will give people a deeper understanding of the medical, behavioral, and environmental factors that can accelerate disease or optimize health,” according to a recent announcement by Prof. Jun Wang, iCarbonX founder and creator of the Digital Life Alliance, based in Shenzhen, China.

ImmunoSignature, the diagnostic platform developed by a team led by Prof. Stephen Albert Johnston and Prof. Neal Woodbury of Arizona State University (ASU) Biodesign Institute, was a critical final piece needed to complete iCarbonX's potentially revolutionary approach to healthcare. With a single drop of blood, the platform can detect diseases that involve an immune response (e.g. autoimmune, cancer, infectious disease, metabolic, and neurologic diseases). The team has already successfully demonstrated the potential of immunosignaturing for diagnosing over 50 diseases, including diabetes, cancer, and Alzheimer’s.

“My goal has always been to detect illness before it begins,” said Prof. Johnston, adding that he predicts that the technology to track and report disease biomarkers directly to patients could be available within 5 years. Backed by a USD 400 million investment, the Digital Life Alliance aims at producing a personalized health guide, and will, according to Prof. Wang, “merge genetic, biological, and patient-generated data with sequencing and AI (artificial intelligence) technology to instantly detect meaningful signals about health, disease and aging, and deliver a personalized guide for living a healthy life.”

“Scientists with expertise, imagination, and boundless aspiration are who we recruit to Arizona, ASU, and Biodesign,” said ASU President Michael Crow, “Today we are being recognized as a powerhouse in the world of innovation and for generating use-inspired solutions. iCarbonX’s significant investment in technologies conceived at ASU is a real demonstration of what can happen when public and private enterprises bring their best minds together.” Launched in 2004, ASU’s Biodesign Institute represents the state’s largest single investment in research infrastructure in the history of Arizona.

Digital Life Alliance includes HealthTell as one of 7 core companies. According to Prof. Johnston, HealthTell’s high-density peptide array platform is the first real-time assessment that will be simple, inexpensive, and comprehensive. The HealthTell technology, particularly when combined with data from the other Digital Life Alliance partners, has the potential to enable health monitoring on a regular basis using single-drop blood samples.

Catching diseases early save lives, helps eradicate challenges faced by those who suffer from illness, and results in cost savings. Some of the leading causes of disease – both infectious and chronic – give rise to immune responses fairly early. Immunosignatures of antibody patterns that indicate early-response would provide snapshots for monitoring a person’s health as well as a more detailed picture of health status.

“The idea is to change medicine from post-symptomatic to pre-symptomatic. To do that, you have to monitor healthy people and figure out early what’s happening to them,” said Prof. Johnston, With our rapidly aging population and collaborative spirit, he envisions Arizona as a possible “R&D proving ground” to help get ahead of disease and its costs. We “will continue to push the envelope on what health and disease information we can glean from immunosignatures,” he said.

“We can only reach this audacious goal if we successfully integrate traditionally separate fields of expertise into one collaborative ecosystem,” said Prof. Wang. As former CEO of the Beijing Genomics Institute, he has built the world’s largest DNA sequencing hub, which aims to make genomic information a routine part of medical checkups. His iCarbonX ecosystem includes HealthTell, SomaLogic, PatientsLikeMe, AOBiome, GALT, Imagu, and Robustnique.


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.